The Chinese NDRC targets price-related illegal conducts in the pharmaceutical sector

NDRC Targets Price-related Illegal Conducts in the Pharmaceutical Sector* On May 4, 2015, the NDRC published Notice on Reinforcing Supervision over Medical Prices (“Notice”). In the Notice, the NDRC issued a range of specific opinions on the supervision over medical price, including immediately launching special inspections into illegal conducts under Pricing law and AML and some other specific issues. In this article, we would analyze the antitrust issues which may occur in such special inspections, in order to provide advice for antitrust compliance in pharmaceutical sector. The Notice aims to implement the Opinions on Promoting the Drug Pricing Reform (“Opinion”), which was jointly published by the NDRC, the National Health and Family Planning Commission (“NHFPC”), the Ministry of

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • King & Wood Mallesons (Beijing)
  • Freshfields Bruckhaus Deringer (Beijing)

Citation

Susan Ning, Hazel Yin, The Chinese NDRC targets price-related illegal conducts in the pharmaceutical sector, 4 mai 2015, e-Competitions May 2015, Art. N° 73795

Visites 360

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues